There has been federal-provincial-territorial work specifically on the national pharmaceutical strategy. One of the ways in which the federal government supports it--and this committee has looked at the common drug review process--is to provide funding directly to the Canadian agency for assessment of health care technologies, which includes drugs and aspects of the common drug review.
